Although The Pediatric Pulmonary Hypertension Network (PPHNet) guidelines [8] suggest using serial BNP or NT-proBNP levels for monitoring disease severity and response to therapy, there is a distinct lack of data considering these biomarkers levels changes due to applied treatment in BPD-PH patients. This evidence concerns the gene NPPB and bronchopulmonary dysplasia.